Trial Profile
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jun 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Rigosertib (Primary) ; Filgrastim
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Onconova Therapeutics
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 08 Jul 2020 Results published in Onconova Therapeutics media release.
- 19 Jun 2020 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.